GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (CHIX:PEGc) » Definitions » Total Inventories

Pharma Equity Group A/S (CHIX:PEGC) Total Inventories : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharma Equity Group A/S Total Inventories?

Pharma Equity Group A/S's total inventories for the quarter that ended in Dec. 2023 was kr0.00 Mil. Pharma Equity Group A/S's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was kr0.80 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pharma Equity Group A/S's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was kr-0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Pharma Equity Group A/S's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Pharma Equity Group A/S Total Inventories Historical Data

The historical data trend for Pharma Equity Group A/S's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Total Inventories Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.59 1.59 1.59 -

Pharma Equity Group A/S Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Pharma Equity Group A/S  (CHIX:PEGc) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Pharma Equity Group A/S's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4.231+0.75 * 0+0.5 * 0-42.404
-0-0)/1022.95
=-0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pharma Equity Group A/S's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0.796/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Pharma Equity Group A/S's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=0 / 0.796
=0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharma Equity Group A/S's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.796 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Pharma Equity Group A/S Total Inventories Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (CHIX:PEGC) Business Description

Traded in Other Exchanges
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.

Pharma Equity Group A/S (CHIX:PEGC) Headlines

No Headlines